Telix Pharmaceuticals Limited

Equities

TLX

AU000000TLX2

Biotechnology & Medical Research

Delayed Australian S.E. 05:15:40 18/07/2024 BST 5-day change 1st Jan Change
19.57 AUD -2.15% Intraday chart for Telix Pharmaceuticals Limited +0.95% +94.20%
LockThis article is reserved for members
To unlock the article, REGISTER!
Already a customer? Log In
Telix Pharmaceuticals' Revenue Jumps 55% in Q2; Raises Guidance MT
Australian Shares Jumps to Over Three-Month High Following on Fed Chair Comments MT
Telix Pharmaceuticals Welcomes Proposed Changes to Payments for Diagnostic Radiopharmaceuticals in US; Shares Up 13% MT
Telix Pharmaceuticals Launches $200 Million IPO in US MT
Telix Pharmaceuticals Launches $200 Million US IPO MT
Telix Pharmaceuticals Limited Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Jarden Research Adjusts Telix Pharmaceuticals’ Price Target to AU$16.62 From AU$13.94, Keeps at Buy MT
Telix Pharmaceuticals Completes US FDA Regulatory Submission for Kidney Cancer Imaging Agent MT
Telix Pharma Reports Positive Data from Clinical Study of Prostate Cancer Drug; Shares Surge 15% MT
Commodity, banking stocks help Australian shares snap 3-day slide RE
Telix Pharmaceuticals Submits New Drug Application for Prostate Cancer Imaging Agent to US FDA MT
Telix Pharmaceuticals Limited Submits NDA for New Prostate Cancer Imaging Agent CI
Telix Pharmaceuticals Concludes Proof-of-Concept Study of Advanced Prostate Cancer Drug MT
Telix Pharmaceuticals Files Registration Statement for Nasdaq IPO MT
Telix Pharmaceuticals Limited has filed an IPO in the amount of $100 million. CI
Telix Pharmaceuticals Completes Acquisition of QSAM Biosciences and Drug Samarium-153-DOTMP MT
Bell Potter Downgrades Telix Pharmaceuticals to Hold from Buy, Price Target is AU$14.50 MT
Jarden Adjusts Telix Pharmaceuticals Price Target to AU$13.52 from AU$13.27, Keeps at Buy MT
Telix Pharmaceuticals Limited Reports Unaudited Revenue Results for the First Quarter Ended 31 March 2024 CI
Telix Pharmaceuticals Limited Reaffirms Revenue Guidance for the Year 2024 CI
Telix Pharmaceuticals Logs Nearly $115 Million Revenue in Q1 MT
Telix Pharmaceuticals Secures US FDA Fast-Track Designation for Brain Cancer Imaging Product MT
Telix Pharmaceuticals Limited Announces FDA Fast Track Designation for TLX101-CDx CI
Telix Pharmaceuticals Completes Acquisition of Canadian Firm ARTMS MT
Telix Pharmaceuticals Limited completed the acquisition of ARTMS, INC. CI
Chart Telix Pharmaceuticals Limited
More charts
Telix Pharmaceuticals Limited is an Australia-based biopharmaceutical company. The Company is focused on the development and commercialization of diagnostic and therapeutic radiopharmaceuticals and associated medical devices. It is developing a portfolio of clinical and commercial stage products that aims to address significant unmet medical needs in oncology and rare diseases. Its core pipeline is focused on prostate cancer, renal cancer, brain cancer (glioma) and rare diseases (hematologic cancers and bone marrow conditioning). Its pipelines include TLX591, TLX592 (alpha-RADmAb), TLX591-CDx, TLX250, TLX250-CDx, TLX101, TLX101-CDx, TLX300, TLX300-CDx, TLX66, and TLX66-CDx. TLX591 is a radio antibody-drug conjugate (rADC) directed at prostate-specific membrane antigen (PSMA). Its product QUANTM Irradiation System (QIS), enables production of important medical isotopes such as gallium-68 (68Ga), zirconium-89 (89Zr), technetium-99m (99mTc) and copper-64 (64Cu).
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
20 AUD
Average target price
21.5 AUD
Spread / Average Target
+7.51%
Consensus
  1. Stock Market
  2. Equities
  3. TLX Stock
  4. News Telix Pharmaceuticals Limited
  5. Jarden Adjusts Telix Pharmaceuticals Price Target to AU$13.52 from AU$13.27, Keeps at Buy